Wedad M Abdelraheem1, Rasha M M Khairy2, Alaa I Zaki1, Shaimaa H Zaki1. 1. Department of Microbiology and Immunology, Faculty of Medicine, Minia University, Minia, 61511, Egypt. 2. Department of Microbiology and Immunology, Faculty of Medicine, Minia University, Minia, 61511, Egypt. rashakhiry1@gmail.com.
Abstract
BACKGROUND: Multidrug resistant (MDR) and biofilm producing Staphylococcus aureus strains are usually associated with serious infections. This study aimed to evaluate the antibacterial and antibiofilm-formation effects of zinc oxide nanoparticles (ZnO-NPs) against staphylococcus aureus (S. aureus) isolates. METHODS: A total of 116 S. aureus isolates were recovered from 250 burn wound samples. The antimicrobial/antibiofilm effects of ZnO-NPs against methicillin, vancomycin and linezolid resistant S. aureus (MRSA, VRSA and LRSA) isolates were examined using phenotypic and genotypic methods. The minimum inhibitory concentration (MIC) of ZnO-NPs was determined by microdilution method. The effects of sub-MIC concentrations of ZnO-NPs on biofilm formation and drug resistance in S. aureus were determined by the microtiter plate method. The change in the expression levels of the biofilm encoding genes and resistance genes in S. aureus isolates after treatment with ZnO-NPs was assessed by real time reverse transcriptase PCR (rt-PCR). RESULTS: MICs of ZnO-NPs in S. aureus isolates were (128-2048 µg/ml). The sub-MIC of ZnO-NPs significantly reduced biofilm formation rate (the highest inhibition rate was 76.47% at 1024 µg/ml) and the expression levels of biofilm genes (ica A, ica D and fnb A) with P < 0.001. Moreover, Sub-MIC of ZnO-NPs significantly reduced the rates of MRSA from 81.9 (95 isolates) to 13.30% (15 isolates), VRSA from 33.60 (39 isolates) to 0% and LARSA from 29.30 (34) to 0% as well as the expression levels of resistance genes (mec A, van A and cfr) with P value < 0.001. CONCLUSION: ZnO-NPs can be used as antibiofilm and potent antimicrobial against MRSA, VRSA and LRSA isolates.
BACKGROUND: Multidrug resistant (MDR) and biofilm producing Staphylococcus aureus strains are usually associated with serious infections. This study aimed to evaluate the antibacterial and antibiofilm-formation effects of zinc oxide nanoparticles (ZnO-NPs) against staphylococcus aureus (S. aureus) isolates. METHODS: A total of 116 S. aureus isolates were recovered from 250 burn wound samples. The antimicrobial/antibiofilm effects of ZnO-NPs against methicillin, vancomycin and linezolid resistant S. aureus (MRSA, VRSA and LRSA) isolates were examined using phenotypic and genotypic methods. The minimum inhibitory concentration (MIC) of ZnO-NPs was determined by microdilution method. The effects of sub-MIC concentrations of ZnO-NPs on biofilm formation and drug resistance in S. aureus were determined by the microtiter plate method. The change in the expression levels of the biofilm encoding genes and resistance genes in S. aureus isolates after treatment with ZnO-NPs was assessed by real time reverse transcriptase PCR (rt-PCR). RESULTS: MICs of ZnO-NPs in S. aureus isolates were (128-2048 µg/ml). The sub-MIC of ZnO-NPs significantly reduced biofilm formation rate (the highest inhibition rate was 76.47% at 1024 µg/ml) and the expression levels of biofilm genes (ica A, ica D and fnb A) with P < 0.001. Moreover, Sub-MIC of ZnO-NPs significantly reduced the rates of MRSA from 81.9 (95 isolates) to 13.30% (15 isolates), VRSA from 33.60 (39 isolates) to 0% and LARSA from 29.30 (34) to 0% as well as the expression levels of resistance genes (mec A, van A and cfr) with P value < 0.001. CONCLUSION: ZnO-NPs can be used as antibiofilm and potent antimicrobial against MRSA, VRSA and LRSA isolates.
Authors: Gracia Morales; Juan J Picazo; Elvira Baos; Francisco J Candel; Ana Arribi; Beatriz Peláez; Raquel Andrade; María-Angeles de la Torre; José Fereres; Miguel Sánchez-García Journal: Clin Infect Dis Date: 2010-03-15 Impact factor: 9.079
Authors: Rodrigo E Mendes; Lalitagauri M Deshpande; Mariana Castanheira; Joseph DiPersio; Michael A Saubolle; Ronald N Jones Journal: Antimicrob Agents Chemother Date: 2008-04-07 Impact factor: 5.191
Authors: Venkata G Meka; Satish K Pillai; George Sakoulas; Christine Wennersten; Lata Venkataraman; Paola C DeGirolami; George M Eliopoulos; Robert C Moellering; Howard S Gold Journal: J Infect Dis Date: 2004-06-09 Impact factor: 5.226
Authors: Choonkeun Kim; Catarina Milheiriço; Susana Gardete; Mark A Holmes; Matt T G Holden; Hermínia de Lencastre; Alexander Tomasz Journal: J Biol Chem Date: 2012-09-12 Impact factor: 5.157
Authors: Pranjali P Mahamuni; Pooja M Patil; Maruti J Dhanavade; Manohar V Badiger; Prem G Shadija; Abhishek C Lokhande; Raghvendra A Bohara Journal: Biochem Biophys Rep Date: 2018-12-12
Authors: Sebastián Higuera-Llantén; Felipe Vásquez-Ponce; Beatriz Barrientos-Espinoza; Fernando O Mardones; Sergio H Marshall; Jorge Olivares-Pacheco Journal: PLoS One Date: 2018-09-11 Impact factor: 3.240